Sign In
Buy IFRX
$1.70
-0.0200 (-1.16%)
At Close: Jul 31, 2026
InflaRx to Report Second Quarter 2026 Results on August 6, 2026
07:30am, Thursday, 30'th Jul 2026
Jena, Germany, July 30, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announce
Reviewing InflaRx (NASDAQ:IFRX) and Kamada (NASDAQ:KMDA)
01:59am, Sunday, 26'th Jul 2026
Kamada (NASDAQ: KMDA - Get Free Report) and InflaRx (NASDAQ: IFRX - Get Free Report) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based
InflaRx Assessing Feasibility of Broadened Strategy for ANCA‑Associated Vasculitis in Europe Following EMA Recommendation on Tavneos
07:30am, Tuesday, 30'th Jun 2026
Jena, Germany, June 30, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announce
InflaRx N.V. (IFRX) Discusses Strategic Focus on Izicopan for ANCA-Associated Vasculitis and Renal Diseases Transcript
09:51pm, Friday, 08'th May 2026
InflaRx N.V. (IFRX) Discusses Strategic Focus on Izicopan for ANCA-Associated Vasculitis and Renal Diseases Transcript
InflaRx Investor Update: Izicopan Set to Take Center Stage in AAV and Renal Disease Pipeline
04:04pm, Friday, 08'th May 2026
InflaRx NASDAQ: IFRX outlined plans to prioritize development of izicopan, an oral inhibitor of the C5a receptor (C5aR), in ANCA-associated vasculitis (AAV) and other renal diseases during a company c
InflaRx Announces Closing of $150 Million Underwritten Offering of Ordinary Shares
08:15am, Friday, 08'th May 2026
Jena, Germany, May 08, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX) (the “Company”), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system
InflaRx Announces Pricing of $150 Million Underwritten Offering of Ordinary Shares
08:30am, Wednesday, 06'th May 2026
Jena, Germany, May 06, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX) (the “Company”), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system,
InflaRx Announces Advancement of Izicopan in ANCA-Associated Vasculitis and Select Renal Diseases
08:25am, Wednesday, 06'th May 2026
Jena, Germany, May 06, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced
InflaRx Reports Favorable Reactive Metabolite Profile for Izicopan in Human Liver Microsomes
07:30am, Monday, 04'th May 2026
JENA, Germany, May 04, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced n
InflaRx to Report First Quarter 2026 Results on May 7, 2026
07:30am, Friday, 01'st May 2026
JENA, Germany, May 01, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced t
InflaRx Regains Compliance with Nasdaq Minimum Bid Price Requirement
07:30am, Tuesday, 28'th Apr 2026
JENA, Germany, April 28, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system (the “Company�
InflaRx Reports New Mechanistic Data for Izicopan Supporting its Potential as a Best-in-Class C5aR Inhibitor
07:30am, Thursday, 09'th Apr 2026
JENA, Germany, April 09, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced
InflaRx Announces Participation in the Raymond James 2026 Biotech Innovation Symposium
07:30am, Tuesday, 31'st Mar 2026
JENA, Germany, March 31, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced
Jena, Germany, March 30, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announc
InflaRx N.V. (NASDAQ:IFRX) Receives $6.17 Consensus PT from Analysts
03:17am, Monday, 30'th Mar 2026
InflaRx N.V. (NASDAQ: IFRX - Get Free Report) has been assigned a consensus recommendation of "Moderate Buy" from the seven brokerages that are currently covering the company, Marketbeat Ratings repor
